Harnessing natural killer cell memory to fight viruses
Harnessing natural killer cell memory to fight viruses
批准号:
8571323
负责人:
Catherine A Blish
金额:
$238.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-30 至 2018-06-30
关键词:
AddressAlgorithmsAntigensAntiviral AgentsAntiviral ResponseAutologousBiological AssayCell physiologyCellsCommunicable DiseasesComplementComplexCytomegalovirusCytometryDataDevelopmentFluorescenceHIVImmune responseIn VitroInfection ControlInfluenzaLymphocyteMeasuresMemoryMethodsMorbidity - disease rateNatural Killer CellsPhenotypePopulationSurfaceTechniquesTherapeuticTimeVaccinationVaccinesViralVirusVirus Diseasescombinatorialfightinginnovationinsightkillingsmortalitynew technologynovel strategiespreventreceptorresponsetraitvaccine development
中文摘要
描述(由申请人提供):疫苗接种是预防与传染病相关的发病率和死亡率的最有效方法之一,但有许多病毒感染,如人类免疫缺陷病毒(HIV)和巨细胞病毒(CMV),仍然迫切需要持久的,广泛交叉保护的疫苗。尽管大多数疫苗开发的重点是适应性免疫反应,但自然杀伤细胞(NK)是先天淋巴细胞应答者,可以快速而有力地杀死病毒感染的细胞。最近的数据表明,NK细胞具有适应性免疫反应的特征,包括对同一抗原的第二次攻击做出更快、更有力的反应的能力。因此,在适应性免疫反应太少和太晚的情况下,它们在疫苗或治疗环境中建立早期感染控制方面显示出巨大的希望。在这种反应能够成功地引发之前,NK细胞必须识别病毒感染的细胞
英文摘要
DESCRIPTION (provided by applicant): Vaccination is one of the most effective methods to prevent morbidity and mortality related to infectious diseases, yet there are many viral infections, such as Human Immunodeficiency Virus (HIV) and cytomegalovirus (CMV), for which durable, broadly cross-protective vaccines remain desperately needed. Although most of the focus in vaccine development has been on adaptive immune responses, natural killer (NK) cells are innate lymphocyte responders that rapidly and robustly kill virus-infected cells. Recent data has demonstrated that NK cells share features of adaptive immune responses-including the ability to respond more quickly and robustly upon a second challenge with the same antigen. Thus, they show great promise in establishing early control of infection in a vaccine or therapeutic setting where adaptive immune responses have proven to be too little and too late. Before this response can be elicited successfully, NK cell recognition of virus-infected cells must
be understood at a detailed level. However, NK cells are a highly heterogeneous cell population, capable of a vast variety of functions and possessing a complex mosaic of surface receptors. The limits of fluorescence cytometry have prevented the simultaneous examination of all of these traits. To address this question, we propose the use of a novel technology, Cytometry by Time-Of-Flight (CyTOF). CyTOF can detect up to 40 cellular markers simultaneously, a considerable advance from the traditional fluorescence cytometry limit of 12-18. Thus, we will use CyTOF to comprehensively measure NK cell phenotype and functions during killing of virus-infected cells. We will define the specific populations of effector NK cells critical for responsesto HIV, influenza, and CMV by developing in vitro viral suppression assays in which NK cells from healthy donors recognize and kill autologous cells infected with these viruses. The highly parametric, deep profiling capabilities of CyTOF, applied to this specific, controlled interrogatio of antiviral NK cell function, will allow us to gain profound insight into which NK cells are activly recognizing and killing virus- infected cells. Results will be analyzed using a variety of complementary statistical techniques and dimensionality reduction algorithms. Once this analysis has defined specific subsets of NK cells involved in killing virus-infected cells, we will
complement these findings using in vitro functional assays to define precisely how the NK cells are recognizing and killing the infected cells. These assays classically examine single receptors or functions, but will be adapted to simultaneously interrogate multiple receptors or functions in a combinatorial manner. Our innovative approach aims to understand which NK cell subsets to prime and which functions to stimulate in order to purposefully elicit an antiviral response in a vaccine or therapeutic setting. Our findings will therefore drive the development of innovative new approaches to vaccination.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pandemic Assistance Core
-
批准号:10514267
-
项目类别:
-
资助金额:$559.9万
-
财政年份:2022
-
负责人:Catherine A Blish
-
依托单位:
Natural killer cell engineering to target the HIV reservoir
-
批准号:10380777
-
项目类别:
-
资助金额:$77.21万
-
财政年份:2021
-
负责人:Catherine A Blish
-
依托单位:
Natural killer cell engineering to target the HIV reservoir
-
批准号:10593137
-
项目类别:
-
资助金额:$76.01万
-
财政年份:2021
-
负责人:Catherine A Blish
-
依托单位:
Targeting natural killer cells to HIV in intravenous drug users
-
批准号:10347303
-
项目类别:
-
资助金额:$78.5万
-
财政年份:2018
-
负责人:Catherine A Blish
-
依托单位:
Diagnostic signatures of Zika virus pathogenesis
-
批准号:9298458
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2017
-
负责人:Catherine A Blish
-
依托单位:
Impact of HIV exposure, feeding status, and microbiome on immune ontogeny and vaccine responses in infants
-
批准号:10116253
-
项目类别:
-
资助金额:$42.1万
-
财政年份:2017
-
负责人:Catherine A Blish
-
依托单位:
Modeling the influence of sex on natural killer cell networks
-
批准号:8994014
-
项目类别:
-
资助金额:$9.87万
-
财政年份:2013
-
负责人:Catherine A Blish
-
依托单位:
Defining Immune Deficits in HIV-1 Infected Women
-
批准号:7766258
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2006
-
负责人:Catherine A Blish
-
依托单位:
Defining Immune Deficits in HIV-1 Infected Women
-
批准号:7192411
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2006
-
负责人:Catherine A Blish
-
依托单位:
Defining Immune Deficits in HIV-1 Infected Women
-
批准号:7379920
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2006
-
负责人:Catherine A Blish
-
依托单位:
Defining Immune Deficits in HIV-1 Infected Women
-
批准号:7575166
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2006
-
负责人:Catherine A Blish
-
依托单位:
Defining Immune Deficits in HIV-1 Infected Women
-
批准号:7062272
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2006
-
负责人:Catherine A Blish
-
依托单位:
海外基金